Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Avoca Quality Consortium Announces 2013 Key Initiatives

Published: Friday, January 25, 2013
Last Updated: Friday, January 25, 2013
Bookmark and Share
Eli Lilly & Co. and Pfizer, Inc. continue as lead Consortium sponsors.

The Avoca Group announced the Avoca Quality Consortium’s 2013 key initiatives. Building upon a successful launch year, the Avoca Quality Consortium will implement additional initiatives aimed at further enabling members to optimize approaches for proactive quality management of outsourced clinical trials.

Formed in January of 2012 with 29 members, The Avoca Quality Consortium brings together executives from pharma, biotech, and clinical research organizations (CROs) to accelerate the development of best practice approaches to quality management. Over the past year, the Consortium successfully completed the creation of a Clinical Quality Agreement template and a Quality Metrics initiative.

“Our overarching goal is to help our diverse members strike the right balance between meeting timelines, ensuring cost containment and achieving the highest level of quality in their clinical trials,” explained Patricia Leuchten, President and CEO of Avoca. “We made tremendous progress during our first year and are now poised to expand the scope of this critically important work.”

For 2013, the Quality Consortium will conduct a consortium-wide research assessment focused on managing risk in outsourced clinical trials. This will include an assessment of Consortium members’ approaches to managing risk compared to the overall industry’s approach.

“At a time of increasing regulatory expectations, industry collaboration to raise the bar on quality in critical trials is more important than ever,” said Jeff Kasher, Ph.D., Vice President, Clinical Trial: Materials, Implementation, and Transformation, Eli Lilly Co. “Our first year work produced very practical tools, which many members have already put into use. Our 2013 focus on guidelines and tools for effective oversight will continue in the same spirit: research that leads to useable tools to support proactive quality management.”

Research and work on leading practices in proactive quality management serve as the two pillars of the Avoca Quality Consortium. Members of the Avoca Quality Consortium will receive 2013 guidelines and tools focused on effective oversight, revisions and refinements to its quality agreement and metrics tools, Avoca research reports, participation in the May Summit and Fall Working Sessions, participation in regular WebEx Meetings and updates on work related to avenues for operationalizing approaches to proactive quality management.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Benefits of Early Antiretroviral Therapy in HIV Infection
Scientists have explored the clinical importance of starting treatment early in individuals suffering with HIV.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!